The University of Southern California (USC) has received a $6m grant from the California Institute for Regenerative Medicine ...

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new first ...

Søren Tulstrup, President and CEO, Hansa Biopharma said, 2024 proved to be a transformative year for Hansa, marked by ongoing commercial success of IDEFIRIX® across Europe and the achievement of key ...

Brain cancer is the second-leading cause of death in children in the developed world. For the children who survive, standard ...

IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced ...

Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice. The novel drug CT-179 was ...

Childhood brain cancer research breakthrough could transform treatment: International study: Atlanta, Georgia Thursday, February 6, 2025, 14:00 Hrs [IST] Brain cancer is the secon ...

A new study reveals that the experimental drug CT-179 targets OLIG2-positive cancer stem cells, preventing tumor recurrence in medulloblastoma. Preclinical trials show the drug crosses the blood-brain ...

Liposuction and plastic surgery aren't often mentioned in the same breath as cancer. But they are the inspiration for a new ...

A new approach that used CRISPR to engineer adipocytes and implant them in mice models of cancer reduced cancer progression.